Amneal Pharmaceuticals, Inc. (AMRX) Financials
AMRX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 3.5 billion | 3.5 billion |
2023-09-30 | 3.7 billion | 3.5 billion |
2023-06-30 | 3.7 billion | 3.5 billion |
2023-03-31 | 3.6 billion | 3.5 billion |
AMRX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 104.1 million | 6.0 million |
2023-09-30 | 67.9 million | 6.7 million |
2023-06-30 | -23.6 million | 6.6 million |
2023-03-31 | 128.0 million | 7.6 million |
AMRX Net Income
No data available :(
AMRX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 91.5 million | - | 109.9 million |
2023-09-30 | 86.9 million | - | 115.3 million |
2023-06-30 | 109.3 million | 2.6 billion | 118.6 million |
2023-03-31 | 144.7 million | 2.6 billion | 121.4 million |
AMRX Shares Outstanding
AMRX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 31.7 million | 46.6 million | 109.0 million | - |
2023-09-30 | 13.5 million | 42.3 million | 113.0 million | - |
2023-06-30 | 12.3 million | 38.6 million | 105.6 million | - |
2023-03-31 | 11.7 million | 40.3 million | 102.1 million | - |
AMRX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 617.0 million | 427.2 million |
2023-09-30 | 620.0 million | 387.5 million |
2023-06-30 | 599.0 million | 379.0 million |
2023-03-31 | 557.5 million | 379.4 million |
AMRX
Price: $5.87
52 week price:
Earnings Per Share: -0.48 USD
P/E Ratio: 92
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 1.8 million
Market Capitalization: 1.7 billion